Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Amylyx Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AMLX
Nasdaq
8731
https://www.amylyx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Amylyx Pharmaceuticals Inc
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
- Apr 12th, 2024 1:22 pm
Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder
- Apr 10th, 2024 7:14 pm
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
- Apr 10th, 2024 5:19 pm
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
- Apr 10th, 2024 1:00 pm
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
- Apr 8th, 2024 1:00 pm
Analysts Just Slashed Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) EPS Numbers
- Apr 6th, 2024 1:11 pm
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
- Apr 4th, 2024 5:20 pm
ALS drug will be pulled from US market after study showed patients didn't benefit
- Apr 4th, 2024 2:05 pm
UPDATE 1-Amylyx Pharma to remove ALS drug from US, Canada markets
- Apr 4th, 2024 11:52 am
Amylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the Market
- Apr 4th, 2024 11:43 am
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
- Apr 4th, 2024 11:00 am
Amylyx to pull ALS drug from market in rare move
- Apr 4th, 2024 10:09 am
European study finds popular ALS drug ineffective
- Mar 27th, 2024 11:36 am
3 Pharma Stocks to Sell in March Before They Crash & Burn
- Mar 14th, 2024 10:49 pm
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
- Mar 14th, 2024 4:07 pm
Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
- Mar 14th, 2024 1:00 pm
Analysts on Wall Street Lower Ratings for These 10 Stocks
- Mar 13th, 2024 1:03 pm
After surprise trial failure, ALS doctors brace for one less treatment option
- Mar 12th, 2024 11:55 am
Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%
- Mar 11th, 2024 4:34 pm
Amylyx CEOs look for a path forward following major setback
- Mar 11th, 2024 11:45 am
Scroll